{"url_path":"/sec/idxg/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1054102/0001493152-26-022508-index.html","accession_number":"0001493152-26-022508","cik":"0001054102","ticker":"IDXG","issuer_name":"INTERPACE BIOSCIENCES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1054102/0001493152-26-022508-index.html","primary_entity_key":"0001054102","primary_entity_name":"INTERPACE BIOSCIENCES, INC."},"word_count":693,"has_tables":true,"body_markdown":"false\nQ1\n--12-31\n0001054102\n\n0001054102\n\n2026-01-01\n2026-03-31\n\n0001054102\n\n2026-05-01\n\n0001054102\n\n2026-03-31\n\n0001054102\n\n2025-12-31\n\n0001054102\n\nus-gaap:SeriesCPreferredStockMember\n\n2026-03-31\n\n0001054102\n\nus-gaap:SeriesCPreferredStockMember\n\n2025-12-31\n\n0001054102\n\nus-gaap:TreasuryStockCommonMember\n\n2026-03-31\n\n0001054102\n\nus-gaap:TreasuryStockCommonMember\n\n2025-12-31\n\n0001054102\n\n2025-01-01\n2025-03-31\n\n0001054102\n\nus-gaap:PreferredStockMember\n\n2024-12-31\n\n0001054102\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001054102\n\nus-gaap:TreasuryStockCommonMember\n\n2024-12-31\n\n0001054102\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001054102\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001054102\n\n2024-12-31\n\n0001054102\n\nus-gaap:PreferredStockMember\n\n2025-12-31\n\n0001054102\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001054102\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001054102\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001054102\n\nus-gaap:PreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0001054102\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001054102\n\nus-gaap:TreasuryStockCommonMember\n\n2025-01-01\n2025-03-31\n\n0001054102\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001054102\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001054102\n\nus-gaap:PreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001054102\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001054102\n\nus-gaap:TreasuryStockCommonMember\n\n2026-01-01\n2026-03-31\n\n0001054102\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001054102\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001054102\n\nus-gaap:PreferredStockMember\n\n2025-03-31\n\n0001054102\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001054102\n\nus-gaap:TreasuryStockCommonMember\n\n2025-03-31\n\n0001054102\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001054102\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001054102\n\n2025-03-31\n\n0001054102\n\nus-gaap:PreferredStockMember\n\n2026-03-31\n\n0001054102\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001054102\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001054102\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001054102\n\nus-gaap:SubsequentEventMember\n\n2026-05-01\n\n0001054102\n\n2021-02-28\n\n0001054102\n\nus-gaap:DiscontinuedOperationsDisposedOfBySaleMember\n\n2026-01-01\n2026-03-31\n\n0001054102\n\nus-gaap:DiscontinuedOperationsDisposedOfBySaleMember\n\n2025-01-01\n2025-03-31\n\n0001054102\n\nus-gaap:EmployeeStockOptionMember\n\n2026-01-01\n2026-03-31\n\n0001054102\n\nus-gaap:EmployeeStockOptionMember\n\n2025-01-01\n2025-03-31\n\n0001054102\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2026-01-01\n2026-03-31\n\n0001054102\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2025-01-01\n2025-03-31\n\n0001054102\n\nIDXG:StockIncentivePlanMember\n\n2026-01-01\n2026-03-31\n\n0001054102\n\nIDXG:SalesAndMarketingMember\n\n2026-01-01\n2026-03-31\n\n0001054102\n\nIDXG:SalesAndMarketingMember\n\n2025-01-01\n2025-03-31\n\n0001054102\n\nIDXG:GeneralAndAdministrativeMember\n\n2026-01-01\n2026-03-31\n\n0001054102\n\nIDXG:GeneralAndAdministrativeMember\n\n2025-01-01\n2025-03-31\n\n0001054102\n\nus-gaap:SeriesBPreferredStockMember\nIDXG:ExchangeAgreementMember\n\n2024-10-10\n2024-10-10\n\n0001054102\n\nus-gaap:SeriesBPreferredStockMember\nIDXG:AmpersandLimitedPartnersMember\nIDXG:ExchangeAgreementMember\n\n2024-10-10\n2024-10-10\n\n0001054102\n\nus-gaap:SeriesBPreferredStockMember\nIDXG:OneThreeOneFiveCapitalMember\nIDXG:ExchangeAgreementMember\n\n2024-10-10\n2024-10-10\n\n0001054102\n\nus-gaap:SeriesCPreferredStockMember\nIDXG:ExchangeAgreementMember\n\n2024-10-10\n2024-10-10\n\n0001054102\n\nus-gaap:SeriesCPreferredStockMember\nIDXG:ExchangeAgreementMember\n\n2024-10-10\n\n0001054102\n\nus-gaap:SeriesCPreferredStockMember\nIDXG:AmpersandLimitedPartnersMember\nIDXG:ExchangeAgreementMember\n\n2024-10-10\n2024-10-10\n\n0001054102\n\nus-gaap:SeriesCPreferredStockMember\nIDXG:OneThreeOneFiveCapitalMember\nIDXG:ExchangeAgreementMember\n\n2024-10-10\n2024-10-10\n\n0001054102\n\nus-gaap:SeriesCPreferredStockMember\nIDXG:OneThreeOneFiveCapitalMember\nIDXG:ExchangeAgreementMember\n\n2024-10-10\n\n0001054102\n\nus-gaap:SeriesCPreferredStockMember\n\n2026-01-20\n2026-01-20\n\n0001054102\n\nus-gaap:SeriesCPreferredStockMember\n\n2026-01-20\n\n0001054102\n\nIDXG:OneThreeOneFiveCapitalMember\n\n2026-01-20\n\n0001054102\n\nIDXG:OneThreeOneFiveCapitalMember\n\n2026-01-20\n2026-01-20\n\n0001054102\n\nIDXG:AmpersandLimitedPartnersMember\n\n2026-01-20\n\n0001054102\n\nIDXG:AmpersandLimitedPartnersMember\n\n2026-01-20\n2026-01-20\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n10-Q**\n\n \n\n**(Mark\nOne)**\n\n \n\n☒\n**QUARTERLY\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe quarterly period ended March 31, 2026**\n\n \n\n**OR**\n\n \n\n☐\n**TRANSITION\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe transition period from _______________ to _______________**\n\n \n\n**Commission\nFile Number: 000-24249**\n\n \n\n**Interpace Biosciences, Inc.**\n\n \n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Delaware**\n \n**22-2919486**\n\n(State\nor other jurisdiction of\n\nincorporation\nor organization)\n\n \n\n(I.R.S.\nEmployer\n\nIdentification\nNo.)\n\n \n\n**Waterview Plaza, Suite 310, 2001 Route 46, Parsippany, NJ 07054**\n\n \n\n(Address of principal executive offices and zip code)\n\n \n\n**(855) 776-6419**\n\n(Registrant’s telephone number, including area code)\n\n \n\n**Securities\nregistered pursuant to Section 12(b) of the Act:**\n\n \n\nTitle\nof each class\n \nTrading\nSymbol(s)\n \nName\nof each exchange on which registered\n\nNone\n \nN/A\n \nN/A\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule\n405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant\nwas required to submit such files). Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting\ncompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”\n“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge\naccelerated filer ☐\n \nAccelerated\nfiler ☐\n\nNon-accelerated\nfiler ☒\n \nSmaller\nreporting company ☒\n\n \n \nEmerging\nGrowth Company ☐\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nIndicate\nthe number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:\n\n \n\n**Class**\n** **\n**Shares\nOutstanding May 1, 2026**\n\nCommon\nStock, par value $0.01 per share\n \n27,700,904\n\n \n\n \n\n \n\n \n\n \n\n \n\n**INTERPACE\nBIOSCIENCES, INC.**\n\n**FORM\n10-Q FOR PERIOD ENDED MARCH 31, 2026**\n\n**TABLE\nOF CONTENTS**\n\n \n\n \n \n**Page\nNo.**\n\n \n \n \n\n \n**PART I - FINANCIAL INFORMATION**"}